ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Denali Announces Fast Track Designation to DNL310 for Hunter Syndrome
March 18, 2021Denali Therapeutics announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ETV:IDS (DNL310) for the treatment of patients with Hunter syndrome (MPS II). -
Uni of Manchester partners with AVROBIO for Hunter syndrome gene therapy
October 10, 2020The University of Manchester in the UK has partnered with US-based biotech AVROBIO on the clinical development of an investigational gene therapy for mucopolysaccharidosis type II (MPS II), or Hunter syndrome. -
Shire's Hunter Syndrome Treatment Failed Phase II/III Goals
December 20, 2017An experimental treatment to address cognitive impairment in pediatric patients diagnosed with the rare disease known as Hunter syndrome failed a key trial, Shire PLC announced this morning.
Pharma Sources Insight January 2025
